KINIKSA PHARMACEUTICALS INTE (KNSA) Fundamental Analysis & Valuation

NASDAQ:KNSA • GB00BRXB0C07

Current stock price

46.92 USD
-0.38 (-0.8%)
At close:
46.85 USD
-0.07 (-0.15%)
After Hours:

This KNSA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. KNSA Profitability Analysis

1.1 Basic Checks

  • KNSA had positive earnings in the past year.
  • KNSA had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: KNSA reported negative net income in multiple years.
  • Of the past 5 years KNSA 4 years had a positive operating cash flow.
KNSA Yearly Net Income VS EBIT VS OCF VS FCFKNSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • The Return On Assets of KNSA (7.73%) is better than 92.64% of its industry peers.
  • Looking at the Return On Equity, with a value of 10.40%, KNSA belongs to the top of the industry, outperforming 92.64% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 8.21%, KNSA belongs to the best of the industry, outperforming 92.05% of the companies in the same industry.
Industry RankSector Rank
ROA 7.73%
ROE 10.4%
ROIC 8.21%
ROA(3y)0.99%
ROA(5y)-5%
ROE(3y)1.25%
ROE(5y)-7.06%
ROIC(3y)N/A
ROIC(5y)N/A
KNSA Yearly ROA, ROE, ROICKNSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200

1.3 Margins

  • KNSA has a better Profit Margin (8.71%) than 90.50% of its industry peers.
  • KNSA's Profit Margin has declined in the last couple of years.
  • With an excellent Operating Margin value of 11.40%, KNSA belongs to the best of the industry, outperforming 91.09% of the companies in the same industry.
  • KNSA's Operating Margin has improved in the last couple of years.
  • KNSA's Gross Margin of 88.54% is amongst the best of the industry. KNSA outperforms 90.50% of its industry peers.
  • In the last couple of years the Gross Margin of KNSA has remained more or less at the same level.
Industry RankSector Rank
OM 11.4%
PM (TTM) 8.71%
GM 88.54%
OM growth 3Y36.93%
OM growth 5YN/A
PM growth 3Y-52.89%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5YN/A
KNSA Yearly Profit, Operating, Gross MarginsKNSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. KNSA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so KNSA is destroying value.
  • KNSA has more shares outstanding than it did 1 year ago.
  • KNSA has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for KNSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KNSA Yearly Shares OutstandingKNSA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
KNSA Yearly Total Debt VS Total AssetsKNSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 11.98 indicates that KNSA is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 11.98, KNSA belongs to the top of the industry, outperforming 82.95% of the companies in the same industry.
  • KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.98
ROIC/WACC0.88
WACC9.33%
KNSA Yearly LT Debt VS Equity VS FCFKNSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 3.79 indicates that KNSA has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.79, KNSA perfoms like the industry average, outperforming 45.74% of the companies in the same industry.
  • A Quick Ratio of 3.39 indicates that KNSA has no problem at all paying its short term obligations.
  • KNSA has a Quick ratio (3.39) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.79
Quick Ratio 3.39
KNSA Yearly Current Assets VS Current LiabilitesKNSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. KNSA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 221.31% over the past year.
  • The earnings per share for KNSA have been decreasing by -34.14% on average. This is quite bad
  • KNSA shows a strong growth in Revenue. In the last year, the Revenue has grown by 60.09%.
  • Measured over the past years, KNSA shows a very strong growth in Revenue. The Revenue has been growing by 45.45% on average per year.
EPS 1Y (TTM)221.31%
EPS 3Y-34.14%
EPS 5YN/A
EPS Q2Q%241.67%
Revenue 1Y (TTM)60.09%
Revenue growth 3Y45.45%
Revenue growth 5YN/A
Sales Q2Q%64.95%

3.2 Future

  • Based on estimates for the next years, KNSA will show a very strong growth in Earnings Per Share. The EPS will grow by 45.16% on average per year.
  • KNSA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.42% yearly.
EPS Next Y49.06%
EPS Next 2Y49.06%
EPS Next 3Y46.07%
EPS Next 5Y45.16%
Revenue Next Year35.13%
Revenue Next 2Y26.15%
Revenue Next 3Y22.23%
Revenue Next 5Y17.42%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
KNSA Yearly Revenue VS EstimatesKNSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
KNSA Yearly EPS VS EstimatesKNSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

6

4. KNSA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 63.41 indicates a quite expensive valuation of KNSA.
  • Based on the Price/Earnings ratio, KNSA is valued cheaply inside the industry as 89.92% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 27.33. KNSA is valued rather expensively when compared to this.
  • KNSA is valuated quite expensively with a Price/Forward Earnings ratio of 42.54.
  • Based on the Price/Forward Earnings ratio, KNSA is valued cheaper than 90.89% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 38.16. KNSA is around the same levels.
Industry RankSector Rank
PE 63.41
Fwd PE 42.54
KNSA Price Earnings VS Forward Price EarningsKNSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, KNSA is valued cheaply inside the industry as 90.89% of the companies are valued more expensively.
  • KNSA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. KNSA is cheaper than 94.19% of the companies in the same industry.
Industry RankSector Rank
P/FCF 26.33
EV/EBITDA 37.18
KNSA Per share dataKNSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The decent profitability rating of KNSA may justify a higher PE ratio.
  • KNSA's earnings are expected to grow with 46.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.29
PEG (5Y)N/A
EPS Next 2Y49.06%
EPS Next 3Y46.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KNSA Dividend Analysis

5.1 Amount

  • KNSA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KNSA Fundamentals: All Metrics, Ratios and Statistics

KINIKSA PHARMACEUTICALS INTE

NASDAQ:KNSA (4/14/2026, 8:21:17 PM)

After market: 46.85 -0.07 (-0.15%)

46.92

-0.38 (-0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)04-21
Inst Owners103.34%
Inst Owner Change0.02%
Ins Owners3.29%
Ins Owner Change-17.8%
Market Cap3.59B
Revenue(TTM)677.56M
Net Income(TTM)59.01M
Analysts85.71
Price Target56.97 (21.42%)
Short Float %9.25%
Short Ratio6.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-42.87%
Min EPS beat(2)-55.48%
Max EPS beat(2)-30.25%
EPS beat(4)2
Avg EPS beat(4)23.7%
Min EPS beat(4)-55.48%
Max EPS beat(4)156.77%
EPS beat(8)3
Avg EPS beat(8)-795.94%
EPS beat(12)6
Avg EPS beat(12)-483.47%
EPS beat(16)10
Avg EPS beat(16)-333.06%
Revenue beat(2)2
Avg Revenue beat(2)3.78%
Min Revenue beat(2)1.62%
Max Revenue beat(2)5.94%
Revenue beat(4)4
Avg Revenue beat(4)4.02%
Min Revenue beat(4)1.62%
Max Revenue beat(4)5.94%
Revenue beat(8)5
Avg Revenue beat(8)2.71%
Revenue beat(12)9
Avg Revenue beat(12)6.1%
Revenue beat(16)12
Avg Revenue beat(16)8.92%
PT rev (1m)-0.03%
PT rev (3m)2.09%
EPS NQ rev (1m)-25.98%
EPS NQ rev (3m)-36.01%
EPS NY rev (1m)-27.63%
EPS NY rev (3m)-35.89%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)1.37%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)4.26%
Valuation
Industry RankSector Rank
PE 63.41
Fwd PE 42.54
P/S 5.3
P/FCF 26.33
P/OCF 26.03
P/B 6.33
P/tB 6.5
EV/EBITDA 37.18
EPS(TTM)0.74
EY1.58%
EPS(NY)1.1
Fwd EY2.35%
FCF(TTM)1.78
FCFY3.8%
OCF(TTM)1.8
OCFY3.84%
SpS8.85
BVpS7.42
TBVpS7.22
PEG (NY)1.29
PEG (5Y)N/A
Graham Number11.11
Profitability
Industry RankSector Rank
ROA 7.73%
ROE 10.4%
ROCE 12.37%
ROIC 8.21%
ROICexc 24.37%
ROICexgc 26.28%
OM 11.4%
PM (TTM) 8.71%
GM 88.54%
FCFM 20.13%
ROA(3y)0.99%
ROA(5y)-5%
ROE(3y)1.25%
ROE(5y)-7.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y102.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y102.78%
ROICexc growth 5YN/A
OM growth 3Y36.93%
OM growth 5YN/A
PM growth 3Y-52.89%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5YN/A
F-Score8
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 100.9%
Cap/Sales 0.23%
Interest Coverage 250
Cash Conversion 175.16%
Profit Quality 231.2%
Current Ratio 3.79
Quick Ratio 3.39
Altman-Z 11.98
F-Score8
WACC9.33%
ROIC/WACC0.88
Cap/Depr(3y)40.93%
Cap/Depr(5y)198.53%
Cap/Sales(3y)0.11%
Cap/Sales(5y)10.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)221.31%
EPS 3Y-34.14%
EPS 5YN/A
EPS Q2Q%241.67%
EPS Next Y49.06%
EPS Next 2Y49.06%
EPS Next 3Y46.07%
EPS Next 5Y45.16%
Revenue 1Y (TTM)60.09%
Revenue growth 3Y45.45%
Revenue growth 5YN/A
Sales Q2Q%64.95%
Revenue Next Year35.13%
Revenue Next 2Y26.15%
Revenue Next 3Y22.23%
Revenue Next 5Y17.42%
EBIT growth 1Y269.29%
EBIT growth 3Y99.18%
EBIT growth 5YN/A
EBIT Next Year74.43%
EBIT Next 3Y53.01%
EBIT Next 5YN/A
FCF growth 1Y436.82%
FCF growth 3Y188.18%
FCF growth 5YN/A
OCF growth 1Y437.14%
OCF growth 3Y187.44%
OCF growth 5YN/A

KINIKSA PHARMACEUTICALS INTE / KNSA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for KINIKSA PHARMACEUTICALS INTE?

ChartMill assigns a fundamental rating of 7 / 10 to KNSA.


What is the valuation status of KINIKSA PHARMACEUTICALS INTE (KNSA) stock?

ChartMill assigns a valuation rating of 6 / 10 to KINIKSA PHARMACEUTICALS INTE (KNSA). This can be considered as Fairly Valued.


What is the profitability of KNSA stock?

KINIKSA PHARMACEUTICALS INTE (KNSA) has a profitability rating of 7 / 10.


What is the expected EPS growth for KINIKSA PHARMACEUTICALS INTE (KNSA) stock?

The Earnings per Share (EPS) of KINIKSA PHARMACEUTICALS INTE (KNSA) is expected to grow by 49.06% in the next year.